Tomorrow's cardio blockbusters: Inside 'the next big leap' in...

Tomorrow's cardio blockbusters: Inside 'the next big leap' in controlling cholesterol
March 31, 2014 | By Damian Garde
FierceBiotech

Sanofi and Regeneron hit a similar mark in their first Phase III trial of alirocumab, which also topped Merck's small-molecule therapy, and the pair are planning to report 9 more late-stage trials in 2014, unveiling data on roughly 6,000 patients, according to Bill Sasiela, vice president of program direction at Regeneron. Sanofi and Regeneron expect to have long-term data ready by 2018.